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Background: Systolic blood pressure (SBP) increases steadily with age and bears an independent continuous
relationship with the incidence of cardiovascular events. Low-grade inflammation is a suspected pathomechanism
causing vascular aging and promote coronary artery disease (CAD). Recent animal studies give evidence that Toll-like
receptor 4 (TLR4) modulate inflammation and contribute to age-dependent SBP increase. However, there are no data
about TLR4 and age-dependent blood pressure increase in human.
Methods and results: We therefor investigate a human cohort of 2679 patients with CAD aged between 50–80 years.
Genotypes were determined for the TLR4 single nucleotide polymorphism rs4986790 (TLR4 896A/G). Patients
were stratified according to tertiles of age and the upper tertile was compared to lower tertiles.
In this cohort we show that older patients with the TLR4 896 G allele had significantly lower SBP (TLR4 G allele
carriers: 148.2 ± 30.4 mmHg versus A/A allele carrier: 154.9 ± 27.2 mmHg; P < 0.05) and lower pulse pressure (TLR4 G
allele carriers: 69.1 ± 29.7 mmHg versus A/A allele carrier: 75.5 ± 26.4 mmHg; P < 0.05) as compared to TLR4 896A/A
allele carrier.
Conclusion: We demonstrate an association between the TLR4 SNP rs4986790 genotype and age-dependant blood
pressure increase in patients with coronary artery disease.
Keywords: Hypertension, Ageing, Toll-like receptor 4, TLR4Background
Systolic blood pressure (SBP) increases steadily with age
and bears an independent continuous relationship with
the incidence of cardiovascular events [1]. More than
50 % of people aged 60+ are hypertensive and the majority
has isolated systolic hypertension [2]. Among cardiovascu-
lar risk factors amenable to prevention in the elderly,
systolic hypertension is of major importance [3]. Several
interventional trials demonstrated the clinical relevance of
lowering SBP in elderly individuals for reducing cardiovas-
cular events and improving survival [4, 5]. Therefore,
understanding the pathophysiology of SBP increase with* Correspondence: Marcus.Baumann@lrz.tu-muenchen.de
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Chronic low-grade inflammation plays a crucial role in
hypertension during aging [6–9]. This role has been
poorly explored, although chronic low-grade inflamma-
tion has been suggested as an important aspect of aging
as well as coronary artery disease (CAD) [10]. The Toll-
like receptor (TLR) 4 is an evolutionarily ancient pattern
recognition receptor that plays a key role in the innate
immune response [11]. In this context it reflects a major
regulator of inflammation linked to endogenous and
exogenous ligands [12]. Endogenous TLR4 ligands are
present in physiological processes of apoptosis or
necroptosis throughout lifetime [13, 14]. Exogenous
TLR4 ligands like fragments of gram-negative bacterials
are exposed in faeces and the intestinal tract [15].ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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participate in inflammation.
The role of TLR4 polymorphism in CAD and myocardial
infarktion was inconsistant in the literature [16, 17]. Recent
investigations on circulating Toll-like receptor 4 (TLR4)-re-
sponsive miRNA expression shows elevated levesl of TLR4
protein in patients with CAD [18]. Animal data gives first
evidence that TLR4 signaling might contribute to chronic
low-grade inflammation, which influence SBP increase [19]
and hypertension-associated cardiac remodeling [20]. The
common missense mutation Asp299Gly (rs 4986790)
affects the extracellular domain of the TLR4 receptor
and is associated with a blunted response to TLR4 ligands
like lipopolysaccharide (LPS) in humans [21]. Therefore,
we investigated age associated blood pressure increase in a
large clinical cohort of patient with CAD or myocardial in-
farction in relation the functional TLR4 single nucleotide
polymorphism rs 4986790.
Results
We investigated 2679 patients with myocardial infarction
stratified by age and genotype of the functional TLR4
SNP rs4986790 (Asp299Gly) [16]. Dividing the cohort
according to age by tertiles, the genotype distribution of
the polymorphism rs4986790 was not significantly differ-
ent between the age related tertiles. TLR4 896G allele
carriers of the upper age tertile (age ≥70 and <80 years)
had a 7 mmHg significantly lower SBP compared to
homozygot AA allele carriers (TLR4 G allele carriers:
148.2 ± 30.4 mmHg versus A/A allele cariers: 154.9 ±
27.2 mmHg; P < 0.05). This is also correlated to a
reduced number of hypertensive patients in this group
(Table 1). Pulse pressure as marker for aortic damage
was reduced by six mmHg (p < 0.05). Univariate analysisTable 1 Comparison of TLR4 896 A/A and TLR4 896 AG/GG Genotyp
Characteristics Total cohort (n = 2679) Lower and middle
(n = 1772)
Genotype AA AG/GG AA
Patients, n (%) 2393 (89.3) 286 (10.7) 1590 (89.7)
Age, y 65.5 ± 8.0 65.7 ± 8.0 61 ± 5.4
Sex, female % 24 25 20
BMI, kg/m2 27.0 ± 3.8 27.0 ± 4.0 27.3 ± 3.8
SBP, mmHg 150.6 ± 26.8 148.6 ± 28.2 148.2 ± 26.3
DBP, mmHg 79.4 ± 4.3 79.0 ± 4.8 79.7 ± 4.2
PP, mmHg 71.2 ± 26.3 68.8 ± 28.0 69 ± 25.9
HR, bpm 73.8 ± 12.3 73.3 ± 11.7 73.4 ± 12.0
Hypertension, % 69 64 66
Hypercholesterolemia, % 57 57 58
Diabetes, % 22 24 19
Smoking, % 47 49 54
AA versus AG/GG *P < 0.05, Lower age tertiles versus higher age tertile #P < 0.05confirmed age (p < 0.001) and sex (p < 0.001) as commonly
known blood pressure modulating risk factors in all tertiles
of the cohort. Interestingly TLR4 G polymorphism shows a
significant association for SBP (p = 0.017) (Table 2), hyper-
tension (p < 0.001) and pulse pressure (p = 0.026) only in
the upper age tertile (age ≥70 and <80 years) (Additional
file 1: Table S1). These effects were not present in the lower
age tertiles (age ≥50 and <70) (p = 0.56). Multivariate
analysis of the upper age tertile confirm TLR4 896 G
polymorphism as independent predictor of SBP and
hypertension (Table 3)
This analysis demonstrates in humans that 896G allele
carriers older than 70 years reveal lower SBP suggesting
an effect of TLR4 signaling on SBP increase with aging.
Discussion
The increasing incidence of hypertension with age is
thought to be a physiological process which develops
with vascular aging mediated by low-grade inflammation
and oxidative stress. Animal studies demonstrated that
oxidative stress is acutely induced in the aortic tissue by
Toll like receptor 4 (TLR4) ligands. TLR4 are present in
different vascular beds and TLR4 ligands have been
shown to induce chronic low-grade inflammation and
oxidative stress in vascular smooth muscle cells [22, 23].
Even more, endogenous TLR4 ligands are strongly involved
in a mouse model of acute blood pressure increase [19].
We investigated the human TLR4 SNP rs4986790
(Asp299Gly; 896 A/G) in 2679 patients with history of
myocardial infarction [16]. This polymorphism affects
the extracellular domain of the TLR4 receptor and is
associated with a blunted response to inflammatory li-
gands in humans [21]. We could show that carriers of
the TLR4 896 G genotype presented a significant lowere divided by Age Tertiles
age tertiles age ≥50 and <70 Upper age tertile age ≥70 and <80
(n = 907)
AG/GG AA AG/GG
182 (10.3) 803 (88.6) 104 (11.4)
60.9 ± 5.5 74.6 ± 2.8# 74.4 ± 2.6#
21 33# 33#
27.5 ± 4.1 26.5 ± 3.8 26.2 ± 3.6
148.9 ± 26.9 154.9 ± 27.2# 148.2 ± 30.4*
79.2 ± 4.5 79.3 ± 4.6 78.6 ± 5.4
68,5 ± 28.0 75,5 ± 26.4# 69,1 ± 29.7*





Table 2 Univariate analysis for systolic blood pressure of the
whole cohort and devided by tertiles
A: Whole cohort
Parameter
Coefficient B SEM Beta P
Age, y 0.509 0.064 0.151 <0.001
Sex (M = 0,F = 1) 10.943 1.197 0.174 <0.001
BMI, kg/m2 0.05 0.138 0.007 0.7
Diabetes (No = 0, Yes = 1) 3.445 1.256 0.053 0.006
Hypercholesterolemia
(No = 0, Yes = 1)
2.987 1.053 0.055 0.005
TLR4 SNP 896 (AA = 0, AG/GG = 1) −1.595 1.712 −0.018 0.35
B: Lower and middle age tertiles (age ≥50 and <70)
Parameter Coefficient B SEM Beta P
Age, y 0.719 0.114 0.149 <0.001
Sex (M = 0,F = 1) 11.624 1.550 0.176 <0.001
BMI, kg/m2 0.274 0.166 0.04 0.1
Diabetes (No = 0, Yes = 1) 5.755 1.577 0.087 <0.001
Hypercholesterolemia
(No = 0, Yes = 1)
2.416 1.273 0.045 0.058
TLR4 SNP 896 (AA = 0, AG = 1) 1.211 2.092 0.014 0.56
C: Upper age tertile (age ≥70 and <80)
Parameter Coefficient B SEM Beta P
Age, y 0.492 0.324 0.051 0.13
Sex (M = 0,F = 1) 8.324 1.938 0.142 <0.001
BMI, kg/m2 −0.148 0.246 −0.021 0.54
Diabetes (No = 0, Yes = 1) −1509 2.075 −0.024 0.46
Hypercholesterolemia
(No = 0, Yes = 1)
4.716 1.845 0.085 0.011
TLR4 SNP 896 (AA = 0, AG/GG = 1) −7.023 2.931 −0.08 0.017
Table 3 Multivariate analysis for systolic blood pressure and
hypertension of upper age tertile (age ≥70 and <80)
A: Dependent variable: Systolic blood pressure
Parameter Coefficient B SEM Beta P
Age, y 0.351 0.321 0.036 0.27
Sex (M = 0,F = 1) 7.667 1.951 0.13 <0.001
Hypercholesterolemia
(No = 0, Yes = 1)
3.797 1.838 0.068 0.039
TLR4 SNP 896
(AA = 0, AG/GG = 1)
−6.682 2.901 −0.076 0.022
B: Dependent variable:
Hypertension
Parameter Coefficient B SEM Beta P
Age, y 0.007 0.005 0.047 0.16
Sex (M = 0,F = 1) 0.094 0.031 0.1 0.003
Hypercholesterolemia
(No = 0, Yes = 1)
0.056 0.029 0.063 0.057
TLR4 SNP 896
(AA = 0, AG/GG = 1)
−0.160 0.046 −0.114 0.001
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vestigating genetic variants which influence on blood
pressure did neither detect an association with TLR4
[24] nor the SNP rs4986790 [25]. This is explained by the
relatively low mean age of the cohorts with 52.5 ± 10.1 years
compared to our cohort with a mean age of 65.7 ± 8.0.years.
Correspondingly a large epidemiological study in young
healthy Finnish subjects showed no association with
Toll-like receptor 4 gene (Asp299Gly) polymorphism
and blood pressure [26]. In this cohort the mean age
was below 40. At this age no significant SBP increase
due to aging is suspected. Other smaller human cohorts
in patients aged 60 had only mild non-significant blood
pressure differences [27, 28]. Another explanation
might be the stratification of the cohort by age in tertiles.
Also, we found no difference in blood pressure when
examining the entire cohort without consideration of age.
But comparison of upper and lower age tertiles identified
a significant association of the TLR4 SNP rs4986790 with
SBP, pulse presser and hypertension. However, no otherstudy included such a large group of aged patients 70+.
Additionally CAD composes a high-risk population with
particular chronic low-grade inflammation which may
have contributed to the blood pressure effect.
Vascular aging is accompanied by vascular damage.
Pulse pressure is an accepted parameter of vascular dam-
age. Our data confirm that patients without the functional
TLR4 SNP have a pulse pressure increase with age corre-
sponding to the general human population [29, 30]. By
contrast, the patients containing the TLR4 loss-of-function
SNP rs4986790 had no increase in pulse pressure. This as-
sociation suggests that increase in pulse pressure with
aging might be affected by TLR4 and ameliorated by the
TLR4 loss-of-function SNP.
The probability of a false negative association result
because of population stratification is relatively low, be-
cause the study participants were consecutively recruited
from a defined geographic area of southern Germany
with limited recent immigration. The sample size allowed
an analysis with 80 % power to detect a six mmHg
decrease of SBP among the carriers of the 896G allele at a
two-sided a-error of 0.05.
In summary, our data indicate for this large cohort of
patients with myocardial infarction that carriers of the
TLR4 SNP rs4986790 starting from the age of 70 years
have a lower SBP and pulse pressure. We propose that
TLR4 signaling influences age-dependent SBP increase
in CAD patients.Conclusion
We demonstrate an association between the TLR4 SNP
rs4986790 genotype and age-dependant blood pressure




Participants were examined at 1. Medizinische Klinik
rechts der Isar, Technischen Universität München or
Deutsches Herzzentrum München. Between 1993 and
2002, patients with myocardial infarction between the
ages of 50 to 80 years were enrolled in a dedicated regis-
try. Written informed consent for genetic analysis was
obtained from all individuals. In no case, consent was
withdrawn. Out of this cohort, patients with cardiogenic
shock and advanced heart insufficiency defined as a SBP
< 100 mmHg were excluded, finally reaching a cohort
size of 2679 individuals. SBP and DBP were determined
under standardized conditions in the laying position
(Cardis, Schwarzer GmbH). Pulse pressure was calcu-
lated from systolic and diastolic blood pressure. Clinical
and laboratory data were prospectively collected in an
online database. Source data check was done with 20 %
of the data. The Institutional Ethics Committee approved
the study protocol and the reported investigations were in
accordance with the principles of the current version of
the Declaration of Helsinki.
Definitions
The diagnosis of myocardial infarction was defined
according to the European Society of Cardiology. Briefly,
patients presenting with chest pain lasting >20 min com-
bined with ST-segment elevation or pathological Q
waves on a surface electrocardiogram. Patients with
myocardial infarction had to show either an angiographic-
ally occluded infarct-related artery or regional wall motion
abnormalities corresponding to the electrocardiographic
infarct localization or both. Systemic arterial hypertension
was defined as a systolic blood pressure of ≥140 mmHg
and/or a diastolic blood pressure of ≥90 mmHg, on at
least two separate occasions, or anti-hypertensive treat-
ment. Hypercholesterolemia was defined as a documented
total cholesterol value ≥240 mg/dL (≥6.2 mmol/L) or
current treatment with cholesterol-lowering medication.
Persons reporting regular smoking in the previous
6 months were considered as current smokers. Diabetes
mellitus was defined as the presence of a fasting gly-
caemia ≥126 mg/dL or patients on antidiabetic treatment.
Determination of TLR4 genotype
A blood sample was drawn from each participant during
the regular routing examination for coronary artery
angiogram. Genomic DNA was extracted from peripheral
blood leukocytes with the QIAamp DNA Blood Kit
(Qiagen, Hilden, Germany) or the High Pure PCR Tem-
plate Preparation Kit (Roche Applied Science, Mannheim,Germany). Genotype analysis was performed with allele-
specific fluorogenic oligonucleotide probes in an assay
combining the polymerase chain reaction (PCR) and the 5′
nuclease reaction (TaqMan technique; Applied Biosystems,
Darmstadt, Germany). Primers and probes were established
with the Primer Express software (version 2.0.0; Applied
Biosystems) after import of a DNA sequence (Homo sa-
piens TLR4 gene, TLR4A allele) deposited under accession
number AF177765 in GenBank (http://www.ncbi.nlm.nih/
entrez/). The primers used for amplification of the 896A/G
SNP (Asp299Gly; rs4986790) were 5′ TTGAAGAATTCC
GATTAGCATACTTAGAC 3′ and 5′ TCACCAGGGAAA
ATGAAGAAACAT 3′. Allele-specific signalling was
accomplished with the use of the fluorogenic dyes 6-
carboxy-fluorescein (FAM) and VIC (proprietary dye of
Applied Biosystems) which were attached to the 5′ end
of the probe oligonucleotides. Minor groove binder
(MGB) groups were conjugated with the 3′ end of the
oligonucleotides to facilitate formation of stable du-
plexes between the probes and their single-stranded
DNA targets. The structures of the probes were as follows
(allele-specific nucleotides are underlined): FAM-5′ CCT
CGATGATATTATTGACT 3′-MGB (for 896A), VIC-5′
CTCGATGGTATTATTG 3′-MGB (for 896G) [31]. Oligo-
nucleotides were synthesized by Applied Biosystems. The
two-step thermocycling procedure consisted of 35 cycles
of denaturation at 92 °C for 15 s and primer annealing and
extension at 60 °C for 1 min. After cycling on a GeneAmp
PCR System 9600 or 9700 (Applied Biosystems), endpoint
fluorescent data acquisition and genotype calling was
achieved on an ABI Prism 7000 Sequence Detection
System (Applied Biosystems). As a control, genotyping
was repeated for 20 % of the samples with the use of
DNA prepared separately from the original blood sample.
The ability of the TaqMan systems to provide correct
genotype data was verified in separate analyses of 200 dif-
ferent PCR products with the allele-discriminating restric-
tion enzyme BccI (New England Biolabs, Frankfurt am
Main, Germany) (896A/G SNP). The results obtained with
the different methods were fully corresponding, which
demonstrated the reliability of the TaqMan systems that
were used for genotyping of the 896A/G SNPs in the
entire study population. Genotype determination was
done by workers who had no knowledge of clinical,
laboratory, or angiographic data of the individuals en-
rolled in the study.
Statistical analysis
Patients in the cohort were divided by age into tertiles.
In order to investigate the age-related effect, the lower
two tertiles were summarized (age ≥50 and <70) and
compared with the upper tertile (age ≥70 and <80). The
association was examined by the univariate analysis
using Spearman’s correlation test. The analysis consisted
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the age tertiles of patients with MI. Association analyses
for SBP and DBP were conducted using linear regres-
sion, and analyses for dichotomous hypertension using
logistic regression Discrete variables are expressed as
counts (percentage) and compared with the use of the
χ2 test or Fisher's exact test, as appropriate. Continu-
ous variables are expressed as mean ± SD and com-
pared by means of the unpaired, two-sided t test.
Genotype frequencies in the case group were com-
pared with values predicted by Hardy–Weinberg equi-
librium with the use of the χ2 test. Univariate analysis
was performed for the whole cohort, upper age tertile
and both lower age tertiles. Multivariate analysis used age,
gender and hypercholesterolemia. Level of significance
was set at p < 0.05.
Additional file
Additional file 1: Table S1. Univariate analysis.
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